The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).

Trial Profile

The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Fluorouracil; Fluorouracil; Oxaliplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2014 New trial record
    • 30 May 2014 Primary endpoint 'complete resection rate' met.
    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top